32 results
Keyword Docetaxel Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Vargatef (updated)
nintedanib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/11/2014,
, Revision: 10, Authorised
chemotherapy medicine called docetaxel in patients who have already … given on the same day as docetaxel and becausedocetaxel is given on day 1 of a 21-day … given on days 2 to 21 with docetaxel being given on day 1. Treatment … -
List item
Human medicine European public assessment report (EPAR): Cyramza
Ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014,, Revision: 7, Authorised
used in combination with docetaxel in patients whose disease … given in combination with docetaxel, the recommended dose is 10 … being given the infusion of docetaxel. Treatment should continue … -
List item
Human medicine European public assessment report (EPAR): Ontruzant (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 15/11/2017,, 
, Revision: 3, Authorised
medicines: with paclitaxel or docetaxel, or with another class of … • in combination with docetaxel for the treatment of those … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Kanjinti
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 16/05/2018,, , Revision: 3, Authorised
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Herzuma
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 08/02/2018,, , Revision: 4, Authorised
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Trazimera
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/07/2018,, , Revision: 1, Authorised
medicines: with paclitaxel or docetaxel, or with another class of … medicines: with paclitaxel or docetaxel, or with another class of … -
List item
Human medicine European public assessment report (EPAR): Ogivri (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 12/12/2018,, , Revision: 1, Authorised
medicines: with paclitaxel or docetaxel, or with another type of medicine … -
List item
Human medicine European public assessment report (EPAR): Tecentriq
atezolizumab, Carcinoma, Transitional Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/09/2017,, Revision: 4, Authorised
another cancer medicine, docetaxel, lived for an average of 10 … 10 months for patients on docetaxel. What are the risks associated … another cancer medicine, docetaxel, lived for an average of 10 … -
List item
Human medicine European public assessment report (EPAR): Opdivo (updated)
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015,, Revision: 24, Authorised
compared with 9.4 months with docetaxel. For squamous NSCLC, a study … months in patients given docetaxel. Supportive information was … -
List item
Human medicine European public assessment report (EPAR): Xalkori (updated)
crizotinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 23/10/2012,, Revision: 25, Authorised
with either pemetrexed or docetaxel. In another study in 343 … with either pemetrexed or docetaxel. In another study in 343 patients … -
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015,, Revision: 17, Authorised
another cancer medicine called docetaxel (around 8 months) and the … by the doctor (paclitaxel, docetaxel or vinflunine). Patients … another cancer medicine called docetaxel (around 8 months) and the … -
List item
Human medicine European public assessment report (EPAR): Lonquex (updated)
lipegfilgrastim, Neutropenia
Date of authorisation: 25/07/2013,, Revision: 15, Authorised
-
List item
Human medicine European public assessment report (EPAR): Caprelsa (updated)
Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012,, 
, Revision: 15, Authorised
-
List item
Human medicine European public assessment report (EPAR): Accofil
filgrastim, Neutropenia
Date of authorisation: 17/09/2014,, , Revision: 9, Authorised
-
List item
Human medicine European public assessment report (EPAR): Ketoconazole HRA
Ketoconazole, Cushing Syndrome
Date of authorisation: 18/11/2014,, 
, Revision: 8, Authorised
-
List item
Human medicine European public assessment report (EPAR): Sylvant
siltuximab, Giant Lymph Node Hyperplasia
Date of authorisation: 22/05/2014,, , Revision: 8, Authorised
-
List item
Human medicine European public assessment report (EPAR): Cabometyx
cabozantinib s-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016,, Revision: 4, Authorised
-
List item
Human medicine European public assessment report (EPAR): Yescarta
axicabtagene ciloleucel, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018,, , Revision: 1, Authorised
-
List item
Human medicine European public assessment report (EPAR): Zejula
niraparib tosylate monohydrate, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Date of authorisation: 16/11/2017,, , Revision: 4, Authorised
-
List item
Human medicine European public assessment report (EPAR): Tagrisso
osimertinib mesylate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,, Revision: 8, Authorised
-
List item
Human medicine European public assessment report (EPAR): Grastofil
filgrastim, Neutropenia
Date of authorisation: 17/10/2013,, , Revision: 10, Authorised
-
List item
Human medicine European public assessment report (EPAR): Lynparza
Olaparib, Ovarian Neoplasms
Date of authorisation: 16/12/2014,, Revision: 5, Authorised
-
List item
Human medicine European public assessment report (EPAR): Xofigo
radium Ra223 dichloride, Prostatic Neoplasms
Date of authorisation: 13/11/2013,
, , Revision: 10, Authorised
-
List item
Human medicine European public assessment report (EPAR): Alecensa
alectinib hydrochloride, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 16/02/2017,, Revision: 7, Authorised
-
List item
Human medicine European public assessment report (EPAR): Farydak
panobinostat lactate anhydrous, Multiple Myeloma
Date of authorisation: 28/08/2015,, , Revision: 5, Authorised